Search

Displaying results 1811 - 1820 of 8412 in total
  1. Drug

    PD-168393

    go.drugbank.com/drugs/DB07662
    Experimental

    PD-168393 is an epidermal growth factor receptor inhibitor.

  2. Drug

    Sumanirole

    go.drugbank.com/drugs/DB06477
    Investigational

  3. Drug

    Rilzabrutinib

    go.drugbank.com/drugs/DB17709
    ApprovedInvestigational

    [L53743] ITP is an autoimmune disorder characterized by low platelet count. … Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune

    Synonyms: (3R)-3-[4-Amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-?-[2-methyl-2-[4-(3-oxetanyl)-1-piperazinyl]propylidene]-?-oxo-1-piperidinepropanenitrile, (e/z)-(r)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrileCategories: P-glycoprotein inhibitors, P-glycoprotein substrates
  4. Drug

    Acetarsol

    go.drugbank.com/drugs/DB13268
    ApprovedWithdrawn

    It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964. It has been canceled and withdrawn from the market since August 12, 1997.[L1113]

  5. Drug

    Salmeterol

    go.drugbank.com/drugs/DB00938
    ApprovedInvestigational

    [A190477] Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine.[A183737] Salmeterol was granted FDA approval on 4 February 1994.[L11542]

    Mixtures: FLUSARION EH50/250UG/60 PC, FLUSARION EH50/500UG/60 PCCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Human papillomavirus type 16 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10301
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18.

    Mixtures: Vaccine Vial
  7. Drug

    Human papillomavirus type 18 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10302
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18.

    Mixtures: Vaccine Vial
  8. Drug

    Mafenide

    go.drugbank.com/drugs/DB06795
    ApprovedVet approvedWithdrawn

    In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements

  9. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid … [F3910] eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to diseased cells enabling the cells to carry out dsRNA production internally thereby invoking

  10. Drug

    NAV 1800

    go.drugbank.com/drugs/DB05437
    Experimental

    RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal